<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672035</url>
  </required_header>
  <id_info>
    <org_study_id>ELT202</org_study_id>
    <nct_id>NCT00672035</nct_id>
  </id_info>
  <brief_title>Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study</brief_title>
  <official_title>Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging Study to Assess the Immunogenicity and Safety of LT Application in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercell USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercell USA, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the body's immune response to the LT patch at&#xD;
      different doses.&#xD;
&#xD;
      The secondary purpose of this study is to evaluate the safety of the LT patches at different&#xD;
      doses and the safety of the skin preparation system. Another secondary purpose is to compare&#xD;
      the safety and the body's immune response to LT patches placed on the upper arm versus the&#xD;
      lower back.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dose ranging, multicenter study.&#xD;
      Subjects will be assigned to one of ten treatment groups and vaccinated according to the&#xD;
      study group designation. Treatments will remain the same for first and second vaccinations&#xD;
      (alternating left and right sides).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the immunogenicity of LT application at different doses</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of LT application at different doses</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of the skin preparation system</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare patch performance (safety and immunogenicity) on different anatomical parts of the body</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Traveler's Diarrhea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5µg LT Dose placed at the Deltoid on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5µg LT Dose placed at the Lower Back on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>22.5µg LT Dose placed at the Deltoid on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>22.5µg LT Dose placed at the Lower Back on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>37.5µg LT Dose placed at the Deltoid on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>37.5µg LT Dose placed at the Lower Back on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50µg LT Dose placed at the Deltoid on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50µg LT Dose placed at the Lower Back on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0µg LT) placed at the Deltoid on Day 0 and Day 21</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (0µg LT) placed at the Lower Back on Day 0 and Day 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological: heat-labile enterotoxin of E. coli (LT)</intervention_name>
    <description>LT patch applied on either the deltoid or the lower back.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>10</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects must meet all of the following criteria to be eligible to participate in the&#xD;
        study:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult males or females 18 to 40 years of age with signed informed consent.&#xD;
&#xD;
          -  Women who are not post-menopausal or surgically sterile must have a negative serum or&#xD;
             urine pregnancy test at screening and within 24 hours prior to each vaccination with&#xD;
             understanding (through informed consent process) to not become pregnant over the&#xD;
             duration of the study, and must agree to employ an effective form of birth control for&#xD;
             the duration of the study.&#xD;
&#xD;
          -  Acceptable forms of birth control are: abstinence, hormonal contraceptives (oral,&#xD;
             injectable, implant, patch, ring), double-barrier contraceptives (condom, diaphragm&#xD;
             with spermicide), and IUD.&#xD;
&#xD;
        Subjects meeting any of the following criteria are not eligible for participation in the&#xD;
        study:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory abnormalities.&#xD;
&#xD;
          -  Abnormalities at physical examination&#xD;
&#xD;
          -  Known allergies to any component of the vaccine.&#xD;
&#xD;
          -  Known disturbance of coagulation.&#xD;
&#xD;
          -  Known allergies to adhesives.&#xD;
&#xD;
          -  Participated in unrelated research involving investigational product within 30 days&#xD;
             before planned date of first vaccination.&#xD;
&#xD;
          -  Ever received investigational enterotoxigenic E. coli, LT, or LT(R192G) or NasalFlu,&#xD;
             Berna Biotech, Ltd.&#xD;
&#xD;
          -  Ever received cholera toxin or vaccine (e.g. Orochol™, Dukoral™).&#xD;
&#xD;
          -  Medical history of acute or chronic skin disease at vaccination site(s).&#xD;
&#xD;
          -  Active skin allergy.&#xD;
&#xD;
          -  Recent or regular use of oral or injected steroid medications.&#xD;
&#xD;
          -  Use of immunosuppressive systemic steroid medications including inhaled steroids&#xD;
             within three months prior to first vaccination.&#xD;
&#xD;
          -  Comorbid conditions or treatments that are immunosuppressive, including cancer,&#xD;
             diabetes, end-stage renal disease, as determined by the Investigator.&#xD;
&#xD;
          -  Positive serology for HIV-1, HIV-2, HBsAg, or HCV.&#xD;
&#xD;
          -  History of severe atopy. Signs or history of acute skin infection, sunburn or skin&#xD;
             abnormalities on the vaccination area(s) including fungal infections, severe acne,&#xD;
             history of keloid formation, or active contact dermatitis.&#xD;
&#xD;
          -  Artificial tanning (UV radiation) over the duration of the study including the&#xD;
             screening period.&#xD;
&#xD;
          -  Hirsute (significant amount of hair) at vaccination area(s).&#xD;
&#xD;
          -  Visible tattoos or marks (tattoos/scars) at the vaccination area(s) that would prevent&#xD;
             appropriate dermatological monitoring of the vaccination site(s).&#xD;
&#xD;
          -  Fever equal to or greater than 38.0°C (≥100.4°F) at the time of planned vaccination.&#xD;
&#xD;
          -  Suspicion of or recent history of alcohol or substance abuse.&#xD;
&#xD;
          -  Donated blood or blood products such as plasma within the past 30 days.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Employee of the investigational site.&#xD;
&#xD;
          -  Medical history of achlorhydria.&#xD;
&#xD;
          -  History of abdominal surgery (excluding C-section, hysterectomy, cosmetic surgery,&#xD;
             liposuction, appendectomy, cholecystectomy, ventral hernia repair, and other surgeries&#xD;
             not pertaining to gastrointestinal problems) or history of, or recent acute&#xD;
             gastrointestinal illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Noss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Solano Clinical Research</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QUEST Research Institute</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates PC</name>
      <address>
        <city>Cortland</city>
        <state>New York</state>
        <zip>13045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>May 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LT</keyword>
  <keyword>Healthy Adults</keyword>
  <keyword>Dose Ranging</keyword>
  <keyword>Patch</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

